BVXV's Business Model
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.
| Sector & Industry | Healthcare / Biotechnology |
| Website | https://www.biondvax.com |
| CEO (Chief Executive Officer) | Amir Reichman |
| Number of Employees | |
| IPO date | May 12, 2015 |
BVXV Latest News
|
|
|
|
|
|
|
|
|
|
| Contact | |
|---|---|
| Country | IL |
| Address | Jerusalem BioPark Building |
| City | Jerusalem |
| State | None |
| Phone | 972 8 930 2529 |
| Zip Code | None |
| Other Identifiers | |
| CIK | 0001611747 |
| ISIN | US09073Q1058 |
| CUSIP | 09073Q105 |
| Open | 1.32 |
| Previous Close | 1.35 |
| Volume | 22.67 Thou. |
| Average Volume | 38.94 Thou. |
| Day’s Range | 1.31 – 1.36 |
| 52 Week Range | 0.63-11.49 |
| MA (50) | 1.166322 |
| MA (200) | 1.791246 |
| Market Cap | 4.97 Mil. |
| Shares Out. | 3.65 Mil. |
| Earnings Date | Nov 29, 2023 |
| Beta | |
| Last Dividend | |
| EPS | |
| PE | |
